Kyverna Therapeutics (KYTX) Accumulated Depreciation & Amortization (2023 - 2026)
Kyverna Therapeutics posted quarterly Accumulated Depreciation & Amortization of $200000.0 for Q1 2026, down 33.33% year-on-year from $300000.0 in Q1 2025, and down 94.67% on a QoQ basis from $3.8 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Accumulated Depreciation & Amortization data on file, last reported at $200000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Depreciation & Amortization fell 33.33% year-over-year to $200000.0; the trailing twelve-month figure through Mar 2026 stood at $200000.0 (down 33.33% YoY), and the FY2025 full-year result was $3.8 million, up 2.12% from the prior year.
- Accumulated Depreciation & Amortization for Q1 2026 stood at $200000.0, down from $3.8 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $3.8 million in Q4 2025 and bottomed at $200000.0 in Q1 2023.
- The 4-year median for Accumulated Depreciation & Amortization is $300000.0 (2024), against an average of $993076.9.
- The widest annual swing landed in 2024, when Accumulated Depreciation & Amortization jumped 50.0%; it then slumped 40.0% in 2025.
- A 4-year view of Accumulated Depreciation & Amortization shows it stood at $2.5 million in 2023, then surged by 47.59% to $3.7 million in 2024, then increased by 2.12% to $3.8 million in 2025, then slumped by 94.67% to $200000.0 in 2026.
- The last three Accumulated Depreciation & Amortization figures came in at $200000.0 (Q1 2026), $3.8 million (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 3.75 Mn |
| Dec 31, 2025 | 3.75 Mn |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 3.67 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Dec 31, 2023 | 2.49 Mn |
| Dec 31, 2023 | 2.49 Mn |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |